A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Anthony Elias, MD
Study ID
Protocol Number: 22-0510
More information available at ClinicalTrials.gov: NCT05076591
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers